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Targeting the cation channel 
TRPV4 for bladder dysfunction
Everaerts et al., Proc Natl Acad Sci USA 2010; 107: 19084–19089; 
doi:10.1073/pnas.1005333107
Normal urinary bladder function for the most part occurs 
unconsciously, but the process differs dramatically in a variety 
of conditions. For example, cystitis, bladder outlet obstruction 
due to prostatic enlargement, and overactive bladder syndrome 
can cause frequency, nocturia, urgency, and incontinence and 
negatively affect the quality of life of afflicted patients. Tra-
ditionally, many of these conditions have been treated with 
antimuscarinic agents, which act, at least in part, by reducing 
acetylcholine-induced contraction of the detrusor muscle. How-
ever, their therapeutic efficacy is often limited, and their use can 
be associated with adverse effects such as severe dry mouth, 
constipation, headache, blurred vision, and, particularly in the 
elderly, impaired cognitive function. It was recently found that 
TRPV4, a cation channel of the transient receptor potential 
superfamily, is highly expressed in the urothelial-cell layer of 
the bladder, where it is involved in sensing its filling state. Inter-
estingly, Trpv4−/− mice had a lower voiding frequency and larger 
voided volume than wild-type (WT) mice did. Accordingly, 
Everaerts et al. examined TRPV4 as a potential pharmacologi-
cal target for the treatment of bladder storage dysfunction. They 
used cyclophosphamide-induced cystitis as an experimental 
model of bladder dysfunction, as this chemotherapeutic agent 
is partially metabolized to acrolein, which accumulates in the 
bladder, where it evokes strong hemorrhagic cystitis. Both WT 
and Trpv4−/− mice had similar pathology in the urinary blad-
der after cyclophosphamide administration, but Trpv4−/− mice 
exhibited significantly lower voiding frequencies and larger 
voided volumes than WT animals. The authors next performed 
a high-throughput screen for small-molecule antagonists of 
TRPV4 on a cell line expressing recombinant human TRPV4. 
They focused on HC-067047, a novel and potent and selective 
TRPV4 antagonist that inhibited 4α-phorbol 12,13-didecanoate 
(4α-PDD)-induced Ca2+ responses (Figure). This compound 
reduced frequency and increased bladder capacity in mice and 
rats with cyclophosphamide cystitis. In contrast, TRPV4-defi-
cient mice were insensitive to application of HC-067047. These 
studies show that TRPV4 may be used as a target for treatment 
of bladder dysfunction.
Juan Oliver
Electrostatic cell-surface repulsion 
and lumen formation
Strilić et al., Curr Biol 2010; 20: 2003–2009; doi:10.1016/j.cub.2010.09.061
Although our understanding of kidney homeostasis and diseases 
derives mostly from our knowledge of this organ’s cellular func-
tions, much of the kidney is made of tubules. Many organs in 
the body contain tubular networks, the most prominent being 
the circulatory tree. A key question in biology is how the cen-
tral lumen of blood vessels (and other tubules) develops and is 
maintained. Strilić et al. noted that in vertebrates, mucins and 
proteoglycans are found on the luminal side of many tubular 
organs—for example, the gut, pancreas, salivary gland, lung, 
kidney, and blood vessels—and that these glycoproteins are also 
found on the apical surfaces of invertebrate tubular organs, such 
as the retina, tracheae, and wing imaginal discs of Drosophila, the 
excretory cells of Caenorhabditis elegans, and the midgut of mos-
quitoes. Interestingly, epithelial and endothelial cells express one 
such mucin, the CD34 sialomucin podocalyxin, at the cell–cell 
contact at the onset of lumen formation. The extracellular domain 
of podocalyxin is decorated with oligosaccharides containing 
a large number of negatively charged sialic acids. Because the 
vascular lumen had previously been shown to develop through 
separation of adjacent endothelial cell (EC) surfaces, Strilić et 
al. examined whether sialic acids of apical cell-surface proteins 
contribute an electrostatic repulsion to initiate this process. They 
analyzed the developing mouse aorta, where a temporally and 
spatially defined transition from a non-lumenized EC cord to a 
lumenized tube takes place. They found that sialic acids appeared 
at the cell–cell contact and colocalized with apical podocalyxin, 
suggesting that the sialic acids on apical cell-surface proteins 
positioned to separate apposing EC surfaces from each other. 
Neuraminidase digestion of the sialic acid residues reduced the 
abundance of sialic acids at the endothelial cell–cell contact and 
decreased the frequency of lumenized aorta. Further, dextran sul-
fate bound to the neuraminidase-treated apical cell surface of ECs 
and restored aortic lumen formation despite the absence of sialic 
acids. Moreover, the cationic protamine sulfate also reduced sialic 
acid staining and reduced vascular lumen formation. These and 
other data suggested that sialic acids and their negative charge 
were required on the apical EC surface for initiation of a blood 
vessel lumen in the developing mouse embryo. Using a sprouting 
assay, they also tested whether the same conditions applied to 
Whole-cell patch-clamp recording showing the dose-dependent 
effect of HC-067047 on TRPV4-mediated currents at +80 (red) and −80 
mV (black) in T-REx-HEK-293 cells expressing human TRPV4 (hTRPV4) 
stimulated with 4α-PDD.
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lumen formation during angiogenesis. As shown in the Figure, 
generation of a vascular lumen during angiogenesis requires the 
negative charge of sialic acids. In the aggregate, these findings 
indicate that development of the blood vessel lumen depends 
on the electrostatic repulsion of apposing EC surfaces. Because 
negatively charged glycoproteins, such as mucins and proteogly-
cans, are found on most luminal cell surfaces, such as the ones 
of tracheae, gut tubes, and kidney tubules, among others, it is 
possible that electrostatic repulsion is a general principle used 
to initiate lumen formation in many organs.
Juan Oliver
A novel way of generating 
dendritic cells from monocytes
Cheong et al., Cell 2010; 143: 416–429; doi:10.1016/j.cell.2010.09.039
Dendritic cells (DCs) reside in tissues, including the kidney, 
where they function as ‘immunological sensors’ for danger sig-
nals. Immature DCs capture antigen, change the phenotype, 
and migrate to lymphoid organs, whereas mature DCs opti-
mize clonal selection of rare T and B cells and initiate immune 
responses. DCs appear to derive from a common monocyte–
DC precursor lineage in the bone marrow. However, it remains 
unclear whether cells from the large reservoir of circulating 
monocytes can develop into DCs in vivo. Now, Cheong et al. 
show that circulating monocytes can fully differentiate into 
monocyte-derived DCs (Mo-DCs) in vivo and can be directly 
recruited by lipopolysaccharide from blood into lymph nodes 
in mice. This can occur without the need for special growth fac-
tors, when the monocytes are stimulated by lipopolysaccharide 
through TLR4 and its coreceptor CD14. Using newly developed 
antibodies for mice, they identify DC-SIGN/CD209 as a marker 
for the Mo-DCs in mice. When tested for antigen-presenting 
function, Mo-DCs are as active as classical DCs, including cross-
presentation of proteins and live Gram-negative bacteria on 
MHC I in vivo. Fully differentiated Mo-DCs acquire DC morph-
ology and localize to T-cell areas via L-selectin and CCR7.
Thus, this study by Cheong et al. provides conclusive evidence 
that, in mice, monocytes belong to the extended DC family and 
introduces useful tools to study the role of Mo-DCs in differ-
ent types of immune responses, including kidney diseases and 
transplantation.
Detlef Schlöndorff
Inhibition of prolyl hydroxylases 
increases erythropoietin 
production in ESRD
Bernhardt et al., J Am Soc Nephrol 2010; 21: 2151–2156; doi:10.1681/
ASN.2010010116
This phase II study of the prolyl hydroxylase inhibitor FG-2216 
examined the effect of a single dose of the orally active agent 
in patients with end-stage renal disease (ESRD) both with and 
without native kidneys as well as a healthy volunteer control 
group. Among patients receiving erythrocyte-stimulating 
agents (ESAs) before the study, the mean weekly required dose 
was 9167 units in those with native kidneys and 7333 units in 
those without native kidneys. All ESAs were stopped 7 days 
before study initiation. Participants received a single dose of 
20 mg/kg of FG-2216 and were followed for 7 days. All par-
ticipants saw increases in their plasma erythropoietin (EPO) 
levels. In healthy volunteers, the peak median value was 81.2 
units per liter at 12 hours after dose from a median baseline of 
6.4 units per liter. From a similar baseline, ESRD patients with 
their native kidneys saw the largest rise, with the median level 
of EPO peaking at 240.6 units per liter at 24 hours, whereas the 
ESRD patients without their native kidneys saw a rise similar 
to that in the healthy volunteers (median peak 63.1 units per 
liter). Approximately 11% of FG-2216 was excreted unchanged 
in the urine of the healthy controls within 48 hours. Patients 
with ESRD had an expected higher area under the curve with 
respect to drug levels. However, the dialysis procedure removed 
only 1–2% of FG-2216. Adverse events included diarrhea, 
abdominal discomfort, nausea, rash, headache, hyperkalemia, 
dizziness, sweating, and arterial hypotension. There were no 
serious adverse events related to the study drug.
These results are significant for the insight they provide into 
the potential mechanism of anemia in ESRD as well as for the 
safety data generated for the development of FG-2216. It has 
been assumed that anemia of kidney disease is related to a 
deficiency of EPO resulting from a mechanism of inadequate 
nephrons available for its production. However, the adminis-
tration of FG-2216 clearly resulted in an ability of nephrons 
to increase their capacity to produce EPO, suggesting that the 
mechanism for the anemia may be related more to a desens-
itization of the oxygen-sensing mechanism. Additional phase 
II and III studies of FG-2216 hopefully will shed more light on 
this and other consequences of reviving the kidney’s ability to 
sense oxygenation.
Lynda Szczech
Sialic acids and negative cell-surface charges are required for vascular 
lumen formation during angiogenesis. Lumen formation in angiogenic 
sprouts (top) under control conditions, and after treatment with (middle) 
neuraminidase or (bottom) protamine sulfate. The negative charges of 
sialic acids are shown in green, and the positive charges of protamine 
sulfate are shown in red. The vascular lumen is indicated in yellow.
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